The SWI/SNF complex in cancer — biology, biomarkers and therapy

Nature Reviews Clinical Oncology, Journal Year: 2020, Volume and Issue: 17(7), P. 435 - 448

Published: April 17, 2020

Language: Английский

---

The dormant cancer cell life cycle

Nature reviews. Cancer, Journal Year: 2020, Volume and Issue: 20(7), P. 398 - 411

Published: June 2, 2020

Language: Английский

---

Quantitative evidence for early metastatic seeding in colorectal cancer

Nature Genetics, Journal Year: 2019, Volume and Issue: 51(7), P. 1113 - 1122

Published: June 17, 2019

Language: Английский

---

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

Cancer Cell, Journal Year: 2018, Volume and Issue: 34(6), P. 893 - 905.e8

Published: Dec. 1, 2018

Language: Английский

---

Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes

Cell, Journal Year: 2021, Volume and Issue: 184(8), P. 2239 - 2254.e39

Published: April 1, 2021

Intra-tumor heterogeneity (ITH) is a mechanism of therapeutic resistance and therefore an important clinical challenge. However, the extent, origin, drivers ITH across cancer types are poorly understood. To address this, we extensively characterize whole-genome sequences 2,658 samples spanning 38 types. Nearly all informative (95.1%) contain evidence distinct subclonal expansions with frequent branching relationships between subclones. We observe positive selection driver mutations most identify type-specific patterns gene mutations, fusions, structural variants, copy number alterations as well dynamic changes in mutational processes expansions. Our results underline importance its tumor evolution provide pan-cancer resource comprehensively annotated events from sequencing data.

Language: Английский

---

Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis

Cell, Journal Year: 2019, Volume and Issue: 176(6), P. 1282 - 1294.e20

Published: March 1, 2019

Language: Английский

---

Pathogenesis of Triple-Negative Breast Cancer

Annual Review of Pathology Mechanisms of Disease, Journal Year: 2022, Volume and Issue: 17(1), P. 181 - 204

Published: Jan. 24, 2022

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of fundamentally different diseases with histologic, genomic, and immunologic profiles, which are aggregated under this term because their lack estrogen receptor, progesterone human epidermal growth factor receptor 2 expression. Massively parallel sequencing other omics technologies have demonstrated the level heterogeneity in TNBCs shed light into pathogenesis therapeutically challenging entity cancer. In review, we discuss histologic molecular classifications TNBC, genomic alterations these tumor types harbor, potential impact on tumors. We also explore role microenvironment biology its therapeutic response. Dissecting understanding dependencies each TNBC subtype will be essential to delivering promise precision medicine for patients triple-negative disease.

Language: Английский

---

Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer

Nature Communications, Journal Year: 2018, Volume and Issue: 9(1)

Published: Feb. 23, 2018

Abstract CDK4/6 inhibition substantially improves progression-free survival (PFS) for women with advanced estrogen receptor-positive breast cancer, although there are no predictive biomarkers. Early changes in circulating tumor DNA (ctDNA) level may provide early response prediction, but the impact of heterogeneity is unknown. Here we use plasma samples from patients randomized phase III PALOMA-3 study inhibitor palbociclib and fulvestrant cancer show that relative change PIK3CA ctDNA after 15 days treatment strongly predicts PFS on (hazard ratio 3.94, log-rank p = 0.0013). ESR1 mutations selected by prior hormone therapy shown to be frequently sub clonal, dynamics offering limited prediction clinical outcome. These results suggest a robust biomarker inhibitors, demonstrating divergent clones treatment.

Language: Английский

---

The Hippo signalling pathway and its implications in human health and diseases

Signal Transduction and Targeted Therapy, Journal Year: 2022, Volume and Issue: 7(1)

Published: Nov. 8, 2022

Abstract As an evolutionarily conserved signalling network, the Hippo pathway plays a crucial role in regulation of numerous biological processes. Thus, substantial efforts have been made to understand upstream signals that influence activity pathway, as well its physiological functions, such cell proliferation and differentiation, organ growth, embryogenesis, tissue regeneration/wound healing. However, dysregulation can cause variety diseases, including cancer, eye cardiac pulmonary renal hepatic immune dysfunction. Therefore, therapeutic strategies target dysregulated components might be promising approaches for treatment wide spectrum diseases. Here, we review key critical functions controlled by pathway. Additionally, diseases associated with alterations potential therapies targeting will discussed.

Language: Английский

---

Determinants and clinical implications of chromosomal instability in cancer

Nature Reviews Clinical Oncology, Journal Year: 2018, Volume and Issue: 15(3), P. 139 - 150

Published: Jan. 3, 2018

Language: Английский

---